Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CD52 (Alemtuzumab Biosimilar) antibody

Research Grade Reactivity: Human FACS Host: Humanized Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7093049
  • Target See all CD52 (Alemtuzumab Biosimilar) products
    CD52 (Alemtuzumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    Humanized
    Clonality
    • 1
    Monoclonal
    Conjugate
    • 1
    This CD52 (Alemtuzumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS)
    Purpose
    Anti-CD52 (alemtuzumab biosimilar) mAb
    Characteristics
    Also known as: Campath-1H, LDP-03
    Purification
    Purified from cell culture supernatant by affinity chromatography
    Grade
    Research Grade
    Isotype
    IgG1
  • Application Notes
    Flow Cyt 1:100
    Comment

    Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Reconstitute with deionized water
    Buffer
    Lyophilized from sterile PBS, pH 7.4, 0.1 % Procline 300. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C,-80 °C
    Storage Comment
    Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized proteins are shipped at ambient temperature.
    Expiry Date
    12 months
  • Target
    CD52 (Alemtuzumab Biosimilar)
    Abstract
    CD52 (Alemtuzumab Biosimilar) Products
    Target Type
    Biosimilar
    Background
    Synonyms: CDW52, HE5, CD52, CAMPATH-1 antigen
    Gene ID
    1043
    UniProt
    P31358
You are here: